Authors
Dawn L Hershman, Joseph M Unger, Jason D Wright, Scott Ramsey, Cathee Till, Catherine M Tangen, William E Barlow, Charles Blanke, Ian M Thompson, Maha Hussain
Publication date
2016/4/1
Journal
JAMA oncology
Volume
2
Issue
4
Pages
453-461
Publisher
American Medical Association
Description
Importance
Although intermittent androgen-deprivation therapy (ADT) has not been associated with better overall survival in prostate cancer (PC), it has the potential for lower adverse effects. To our knowledge, the incidence of long-term adverse health events has not been reported.
Objective
To examine long-term late events in elderly patients randomized to intermittent or continuous ADT to determine whether late cardiovascular and endocrine events would be lower in patients treated with intermittent ADT.
Design, Setting, and Participants
This was a secondary analysis of a multicenter clinical trial using linkage between patient data from S9346, a randomized SWOG trial of intermittent vs continuous ADT in men with metastatic PC, and corresponding Medicare claims.
Exposure
Intermittent or continuous ADT.
Main Outcomes and Measures
The main outcome was to identify long-term adverse health events by …
Scholar articles
MM Weissman, OO Berry, V Warner, MJ Gameroff… - JAMA psychiatry, 2016
DL Hershman, JM Unger, JD Wright, S Ramsey, C Till… - JAMA oncology, 2016
DL Hershman, JM Unger, JD Wright, SD Ramsey, C Till… - 2015